Latest Conference Articles

Management of Early Stage Hodgkin Lymphoma Requires “Balancing” Individual Risk

Management of Early Stage Hodgkin Lymphoma Requires “Balancing” Individual Risk

October 10th 2020, 6:15pm

NCCN 2020 Virtual Congress: Hematologic Malignancies

When choosing therapy for patients with early stage Hodgkin lymphoma, considering risk scoring systems and Deauville criteria for PET-adapted therapy are key conditions for optimizing survival rates, according to Ranjana H. Advani, MD.

New Treatment Regimens Used to Provide Maximum Benefit in Multiple Myeloma

New Treatment Regimens Used to Provide Maximum Benefit in Multiple Myeloma

October 10th 2020, 5:15pm

NCCN 2020 Virtual Congress: Hematologic Malignancies

Shaji K. Kumar, MD, discusses the impact of newer treatment regimens for patients with multiple myeloma and his key takeaways from the current landscape.

Limited Activity Shown With Durvalumab/Tremelimumab in Advanced NETs Subtypes

Limited Activity Shown With Durvalumab/Tremelimumab in Advanced NETs Subtypes

September 22nd 2020, 1:00pm

ESMO Congress

Results from the DUNE trial of durvalumab added to tremelimumab in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins showed limited activity, according to a presentation held during the 2020 European Society of Medical Oncology Virtual Congress.

Survival Significantly Improved With Frontline Nivolumab Combo in Gastric/GEJ Cancer and Esophageal Adenocarcinoma

Survival Significantly Improved With Frontline Nivolumab Combo in Gastric/GEJ Cancer and Esophageal Adenocarcinoma

September 21st 2020, 9:30pm

ESMO Congress

Frontline nivolumab plus chemotherapy induced a statistically significant survival benefit compared with chemotherapy alone in patients with newly diagnosed PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma

Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma

September 21st 2020, 9:00pm

ESMO Congress

Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.

Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

September 21st 2020, 9:00pm

ESMO Congress

Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.

Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes

Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes

September 21st 2020, 8:15pm

ESMO Congress

Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.

Atezolizumab Plus Bevacizumab and Chemotherapy Misses PFS End Point in Ovarian Cancer Trial

Atezolizumab Plus Bevacizumab and Chemotherapy Misses PFS End Point in Ovarian Cancer Trial

September 21st 2020, 7:30pm

ESMO Congress

In patients with newly diagnosed stage III/IV ovarian cancer, adding atezolizumab to a backbone combination of bevacizumab and chemotherapy did not improve progression-free survival, missing the primary end point of the phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial presented during the virtual 2020 European Society of Medical Oncology Congress.

Osimertinib Achieves Extended Disease-Free Survival in EGFR-Mutant NSCLC

Osimertinib Achieves Extended Disease-Free Survival in EGFR-Mutant NSCLC

September 21st 2020, 7:15pm

ESMO Congress

In patients with early-stage EGFR mutated non–small cell lung cancer following complete tumor resection, treatment with osimertinib reduced the risk for central nervous system death or progression by 82%, findings presented during the EMSO Virtual Congress 2020.

Palbociclib/Fulvestrant Prolongs PFS in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer

Palbociclib/Fulvestrant Prolongs PFS in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer

September 21st 2020, 6:45pm

ESMO Congress

Patients with endocrine-sensitive hormone receptor–positive, HER2-negative metastatic breast cancer, treated with Frontline fulvestrant in combination with palbociclib experienced improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone, achieving the primary end point of the phase 2 FLIPPER trial.